CLINICAL TRIALS PROFILE FOR BALVERSA

All Clinical Trials for BALVERSA

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02465060 ↗	Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	Recruiting	National Cancer Institute (NCI)	Phase 2	2015-08-12	This phase II MATCH trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic abnormalities (such as mutations, amplifications, or translocations) may benefit more from treatment which targets their tumor's particular genetic abnormality. Identifying these genetic abnormalities first may help doctors plan better treatment for patients with solid tumors, lymphomas, or multiple myeloma.
NCT03155620 ↗	Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)	Recruiting	National Cancer Institute (NCI)	Phase 2	2017-07-24	This Pediatric MATCH screening and multi-sub-study phase II trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and/or for which no standard treatment exists that has been shown to prolong survival. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic changes or abnormalities (mutations) may benefit more from treatment which targets their tumor's particular genetic mutation, and may help doctors plan better treatment for patients with solid tumors or non-Hodgkin lymphomas.
NCT03210714 ↗	Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)	Recruiting	National Cancer Institute (NCI)	Phase 2	2017-11-06	This phase II Pediatric MATCH trial studies how well erdafitinib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders that have spread to other places in the body and have come back or do not respond to treatment with FGFR mutations. Erdafitinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
NCT03999515 ↗	Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate Cancer	Recruiting	Janssen Research & Development, LLC	Phase 2	2020-04-27	This phase II trial studies how well erdafitinib in combination with abiraterone acetate or enzalutamide works in treating patients with double negative prostate cancer. Erdafitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Testosterone can cause the growth of prostate cancer cells. Abiraterone acetate lowers the amount of testosterone made by the body. This may help stop the growth of tumor cells that need testosterone to grow. Enzalutamide blocks the use of testosterone by the tumor cells. Giving erdafitinib with abiraterone acetate or enzalutamide may work better in treating patients with prostate cancer compared to abiraterone acetate or enzalutamide alone.

Clinical Trial Conditions for BALVERSA

Condition Name

Condition Name for BALVERSA
Intervention	Trials
Advanced Malignant Solid Neoplasm	3
Refractory Malignant Solid Neoplasm	3
Recurrent Malignant Solid Neoplasm	3
Recurrent Langerhans Cell Histiocytosis	2

Condition MeSH

Condition MeSH for BALVERSA
Intervention	Trials
Carcinoma	5
Glioma	4
Neoplasms	4
Prostatic Neoplasms	3

Clinical Trial Locations for BALVERSA

Trials by Country

Trials by Country for BALVERSA
Location	Trials
United States	141
Puerto Rico	3
Guam	1
Canada	1

Trials by US State

Trials by US State for BALVERSA
Location	Trials
Washington	4
Texas	4
Arkansas	3
Ohio	3
Arizona	3

Clinical Trial Progress for BALVERSA

Clinical Trial Phase

Clinical Trial Phase for BALVERSA
Clinical Trial Phase	Trials
Phase 2	7
Phase 1	1

Clinical Trial Status

Clinical Trial Status for BALVERSA
Clinical Trial Phase	Trials
Recruiting	5
Not yet recruiting	3

Clinical Trial Sponsors for BALVERSA

Sponsor Name

Sponsor Name for BALVERSA
Sponsor	Trials
National Cancer Institute (NCI)	7
Janssen Research & Development, LLC	1
University of Washington	1

Sponsor Type

Sponsor Type for BALVERSA
Sponsor	Trials
NIH	7
Other	2
Industry	1

Clinical Trials Update, Market Analysis, and Projection for Balversa (Erdafitinib)

Last updated: October 28, 2025

Introduction

Balversa (erdafitinib) represents a targeted therapy in the realm of oncology, specifically designed for the treatment of platinum-refractory metastatic urothelial carcinoma (mUC). Developed and commercialized by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, Balversa was first approved by the U.S. Food and Drug Administration (FDA) in June 2019. This article provides a detailed update on the ongoing clinical trials, market landscape, and future growth projections for Balversa, emphasizing its strategic significance in personalized cancer therapy.

Clinical Trials Update

Regulatory Milestones and Approvals

Initially approved based on Phase II data from the BLC2001 trial—demonstrating an overall response rate (ORR) of 44% in patients with FGFR3 or FGFR2 genetic alterations—Balversa's regulatory journey signals its potential as a transformative treatment. Since its approval, Janssen has sought to expand its label by investigating efficacy in broader patient populations and related cancers.

Ongoing and Completed Clinical Trials

1. Expanded Indications and Combinatorial Strategies

Janssen has initiated multiple clinical trials to evaluate Balversa's efficacy beyond initial approval. These include:

• FPGENT (NCT04810845): A Phase III trial assessing Balversa in combination with pembrolizumab versus chemotherapy in advanced urothelial carcinoma. This trial explores the synergy between FGFR inhibition and immunotherapy.

• FUTURE (NCT04830883): A Phase II study evaluating erdafitinib in patients with FGFR-altered upper tract urothelial carcinoma, aiming to expand its indications.

• Combination with Other Targeted Agents: Trials investigating dual FGFR pathway inhibition or combining Balversa with anti-angiogenic agents to overcome resistance mechanisms are underway.

2. Biomarker-Driven Approach

Given the genetic specificity of Balversa's mechanism—targeting FGFR mutations and fusions—ongoing trials focus heavily on molecular profiling to identify suitable candidates. Such precision medicine approaches bolster treatment efficacy and minimize toxicity.

3. Resistance and Safety Profile

Research into resistance mechanisms continues, especially in cases where patients develop secondary FGFR mutations. Additionally, post-market surveillance and real-world evidence studies have reinforced Balversa's safety profile, with manageable adverse events such as hyperphosphatemia, dry mouth, diarrhea, and fatigue.

Innovative Strategies:

• Real-World Data Collection: Clinical centers worldwide are gathering real-world evidence to evaluate response durability, quality of life, and long-term safety.

• Next-Generation FGFR Inhibitors: Parallel development efforts seek to design next-gen compounds to mitigate resistance issues observed with erdafitinib.

Market Analysis

Market Drivers

The global urothelial carcinoma market is projected to grow notably, driven by:

• Rising Incidence: According to the World Cancer Research Fund, bladder and related urothelial cancers are among the most common worldwide, with an estimated 573,000 new cases globally in 2020 [1].

• Unmet Medical Needs: Limited options exist for patients with FGFR genetic alterations, especially after progression on chemotherapy, positioning Balversa as a critical therapy.

• FDA and Global Approvals: Regulatory acceptance in key markets accelerates adoption and expands access.

Market Size and Growth Projection

1. Current Market Valuation

Primarily targeting the urothelial carcinoma segment, the global market for targeted therapies in bladder cancer was valued at approximately USD 1.2 billion in 2022, with Balversa accounting for a significant share due to its specificity [2].

2. Future Growth Projections

The global urothelial carcinoma targeted therapy market is projected to grow at a Compound Annual Growth Rate (CAGR) of around 12% from 2023 to 2030, reaching an estimated USD 3 billion by 2030. The factors fueling this growth include:

• Expansion of Indications: Potential approval for earlier lines of therapy and combination regimens.

• Biomarker Integration: Increased molecular testing will facilitate precision medicine approaches, expanding eligible patient populations.

• Geographical Expansion: Emerging markets in Asia-Pacific, Latin America, and Eastern Europe demonstrate rising demand for innovative cancer therapies.

Competitive Landscape

Balversa faces competition from emerging FGFR inhibitors such as:

• Infigratinib: Orphan drug approval for FGFR3-mutated bladder cancer.

• Erdafitinib's Differentiation: Its distinct dosing regimen and safety profile, coupled with ongoing trials, position it favorably.

However, the entry of generic versions post-patent expiry and biosimilar competitors could influence pricing and market share over the next decade.

Market Challenges

• Biomarker Testing Accessibility: Ensuring widespread and cost-effective FGFR mutation screening remains a logistical barrier.

• Resistance Development: Overcoming acquired resistance through combination therapies or next-generation inhibitors.

• Pricing and Reimbursement: Balancing high-cost targeted therapies with payer expectations.

Market Projection and Strategic Outlook

Janssen’s strategic focus on expanding indications and optimizing combination therapies will likely sustain Balversa's market growth. Assuming successful Phase III trial outcomes and regulatory approvals in 2024-2025, sales revenue could increase by 20-25% annually, reaching approximately USD 450-500 million by 2026. The expansion into earlier lines of therapy and post-market real-world application will significantly contribute to this trajectory.

The integration of companion diagnostics will further bolster market penetration. Moreover, as the scientific understanding of FGFR-related resistance mechanisms evolves, the development of next-generation inhibitors could redefine the competitive landscape.

Key Takeaways

• Therapeutic Expansion: Ongoing trials aim to extend Balversa's use beyond metastatic urothelial carcinoma, notably in earlier disease stages and combination regimens.

• Market Growth: The global urothelial carcinoma targeted therapy market is poised for substantial growth, driven by increased biomarker-driven treatment and expanding indications.

• Competitive Positioning: Balversa's specificity and ongoing innovation efforts strengthen its competitive edge, although challenges like resistance and pricing remain.

• Strategic Imperatives: Optimization of molecular diagnostics, clinical trial success, and global regulatory approvals are crucial to maximizing Balversa’s market potential.

• Holistic Approach: Integrating real-world evidence with clinical developments will inform future indications and reimbursement strategies.

FAQs

1. What is the current approval status of Balversa?
Balversa was FDA-approved in 2019 for adult patients with locally advanced or metastatic urothelial carcinoma with FGFR3 or FGFR2 genetic alterations, who have progressed during or after platinum-containing chemotherapy.

2. Are there ongoing trials for Balversa in other cancers?
Yes. Trials are investigating Balversa's efficacy in upper tract urothelial carcinomas, as well as in combination with immunotherapy agents such as pembrolizumab, aiming to broaden its indication scope.

3. How does Balversa compare to other FGFR inhibitors?
Balversa is distinguished by its clinical efficacy in FGFR-altered bladder cancer and manageable safety profile. Other inhibitors like infigratinib are in various stages of development, offering alternative options, but balancing efficacy, safety, and resistance profiles remains important.

4. What are the main challenges facing Balversa's market growth?
Key challenges include the need for widespread molecular testing, management of acquired resistance, regulatory delays, and pricing negotiations in different healthcare systems.

5. What is the outlook for Balversa in terms of future sales?
With ongoing trials and expanding indications, sales are expected to grow steadily. Projections estimate revenues reaching USD 450-500 million by 2026, contingent upon positive trial outcomes, regulatory approvals, and payer acceptance.

References

[1] World Cancer Research Fund International. "Bladder Cancer Statistics." 2020.
[2] Grand View Research. "Urothelial Carcinoma Therapeutics Market Size, Share & Trends Analysis." 2023.